Immunogenecity

immunogenecity

Affinity

affinity

Humanization

humanization
technologies infograph technologies infograph monitor

Computer Aided Antibody Design(CAAD)

Traditional Technologies Hybridoma

Traditional Technologies Phage Display

stability

Stability

expression

Expression

developability

Developability

shape

Process

Focusing on growing shareholder value

shape shape
shareholder

Imbalanced Bispecific Antibody Technology Platform "KIH” + commonlight chain format: Similar to Emicizumab "Imbalanced” Dual antigen binding: Best fit for each unique MOA CAAD: Designed common LC + designed ideal biochemical and biophysical features

Biospecific involves a CD3 binder

biospecific shareholder

Biospecific against a CSA (cancer specific antigen) & CAA (cancer associated antigen)

csa shape

Biospecific against one target for CNS and another target on BBB

bba shape

Development of a novel "imbalanced" CSA bispecific antibody by computational design

Case Study
shape
shape shape